Melanom: erst Nivolumab, dann Ipilimumab
نویسندگان
چکیده
منابع مشابه
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic mela...
متن کاملNivolumab plus ipilimumab in the treatment of advanced melanoma
Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment ...
متن کاملInflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
OBJECTIVES Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have demonstrated survival improvements in multiple advanced cancers, but also cause immune-related adverse events (IRAEs). IRAEs with clinical features similar to rheumatic diseases have not been well described. We report patients...
متن کاملImmune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy
CTLA-4: cytotoxic T-lymphocyteeassociated antigen 4 irAEs: immune-related adverse events PD-1: programmed deathe
متن کاملIpilimumab-nivolumab combination therapy leads to biopsy proven immune-mediated pancreatitis
Introduction: Oncologic therapies are continuing to expand and include classes of medications whose primary mechanism of action results in targeted immunotherapy. As with any new therapy, these medications have side effects. In particular, nivolumab and ipilimumab have been associated with side effects involving the gastrointestinal tract, including asymptomatic elevations in pancreatic enzymes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: hautnah dermatologie
سال: 2016
ISSN: 0938-0221,2196-6451
DOI: 10.1007/s15012-016-2272-y